6533b7cefe1ef96bd125708c

RESEARCH PRODUCT

SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients

Maria L. BlascoClara Francés-gómezRon GellerRoberto Gozalbo-roviraDavid NavarroJaime Signes-costaVictor LatorreEliseo AlbertEstela GiménezJesús Rodríguez-díazAlberto MarinaJavier Buesa

subject

0301 basic medicineMaleAntibodies ViralSeverity of Illness IndexGastroenterologylaw.invention0302 clinical medicinelaw030212 general & internal medicinebiologyInflammatory biomarkersMiddle AgedIntensive care unitHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusFemaleAntibodyCoronavirus InfectionsAdultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyPneumonia ViralNeutralizing antibodiesArticleVirus03 medical and health sciencesBetacoronavirusYoung AdultVirologyInternal medicineSeverity of illnessmedicineHumansPandemicsAgedRetrospective StudiesInflammationbusiness.industrySARS-CoV-2C-reactive proteinCOVID-19Retrospective cohort studyAntibodies NeutralizingFerritinbiology.proteinBinding Sites AntibodybusinessBiomarkers

description

Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporterbased pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts. Results The overall correlation between levels of both antibody measurements was good (Rho = 0.82; P = 0 0.1). Four ICU patients died; two of these achieved NtAb50 titers ≥1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0–0.2–<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers. Conclusions The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity.

yearjournalcountryeditionlanguage
2020-10-01
10.1016/j.jcv.2020.104611http://hdl.handle.net/10261/219588